1.24
+0.045(+3.78%)
Currency In USD
| Previous Close | 1.19 |
| Open | 1.22 |
| Day High | 1.25 |
| Day Low | 1.19 |
| 52-Week High | 4.29 |
| 52-Week Low | 0.85 |
| Volume | 318,158 |
| Average Volume | 601,938 |
| Market Cap | 56.45M |
| PE | -1.36 |
| EPS | -0.91 |
| Moving Average 50 Days | 1.33 |
| Moving Average 200 Days | 1.57 |
| Change | 0.05 |
If you invested $1000 in PDS Biotechnology Corporation (PDSB) since IPO date, it would be worth $5.61 as of August 18, 2025 at a share price of $1.235. Whereas If you bought $1000 worth of PDS Biotechnology Corporation (PDSB) shares 5 years ago, it would be worth $417.23 as of August 18, 2025 at a share price of $1.235.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today anno
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
GlobeNewswire Inc.
Jul 10, 2025 12:00 PM GMT
Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort Study Demonstrates Promising Response Rate, Triggering Enrollment Expansion Under Simon Two-Stage DesignPRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Na
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
GlobeNewswire Inc.
Jun 09, 2025 12:00 PM GMT
Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET PRINCETON, N.